ARDX RSI Chart
Last 7 days
0.5%
Last 30 days
19.2%
Last 90 days
-13.6%
Trailing 12 Months
114.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 159.1M | 0 | 0 | 0 |
2023 | 63.1M | 82.9M | 134.3M | 124.5M |
2022 | 4.0M | 5.2M | 9.0M | 52.2M |
2021 | 12.9M | 12.4M | 10.9M | 10.1M |
2020 | 6.6M | 8.3M | 8.0M | 7.6M |
2019 | 0 | 0 | 3.3M | 5.5M |
2018 | 44.3M | 44.4M | 44.5M | 2.6M |
2017 | 0 | 0 | 0 | 60.1M |
2015 | 29.0M | 38.0M | 30.4M | 24.0M |
2014 | 30.9M | 32.8M | 33.8M | 31.6M |
2013 | 11.3M | 17.2M | 23.0M | 28.9M |
2012 | 0 | 0 | 0 | 5.4M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 06, 2024 | felsch robert ora | acquired | 176,445 | 1.48147 | 119,101 | see remarks |
May 06, 2024 | felsch robert ora | sold | -1,831,500 | 8.80581 | -207,988 | see remarks |
May 06, 2024 | grammer elizabeth a | acquired | 410,787 | 1.86775 | 219,937 | see remarks |
May 06, 2024 | grammer elizabeth a | sold | -2,522,220 | 8.87573 | -284,170 | see remarks |
May 03, 2024 | williams laura a | acquired | 29,700 | 0.99 | 30,000 | chief medical officer |
May 03, 2024 | grammer elizabeth a | sold | -405,000 | 9.00 | -45,000 | see remarks |
May 03, 2024 | williams laura a | sold | -333,574 | 8.35 | -39,949 | chief medical officer |
Apr 29, 2024 | raab michael | sold | -192,057 | 6.4019 | -30,000 | president & ceo |
Apr 29, 2024 | raab michael | acquired | 29,700 | 0.99 | 30,000 | president & ceo |
Which funds bought or sold ARDX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 11.39 | 2,116,940 | 8,911,560 | -% |
May 16, 2024 | CASTLEARK MANAGEMENT LLC | new | - | 1,570,960 | 1,570,960 | 0.06% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -0.03 | 254,687 | 1,693,240 | -% |
May 16, 2024 | COMERICA BANK | new | - | 2,811 | 2,811 | -% |
May 16, 2024 | Garner Asset Management Corp | sold off | -100 | -9,270 | - | -% |
May 16, 2024 | Ancora Advisors LLC | unchanged | - | 316 | 2,095 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | added | 445 | 15,792,200 | 18,701,800 | 0.04% |
May 15, 2024 | 683 Capital Management, LLC | sold off | -100 | -1,686,400 | - | -% |
May 15, 2024 | MARSHALL WACE, LLP | new | - | 1,974,400 | 1,974,400 | -% |
May 15, 2024 | Anchor Investment Management, LLC | unchanged | - | 220 | 1,460 | -% |
Unveiling Ardelyx Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Ardelyx Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Ardelyx Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 | 2018Q3 |
Revenue | 33.9% | 46,023,000 | 34,363,000 | 56,391,000 | 22,333,000 | 11,369,000 | 44,178,000 | 4,986,000 | 2,526,000 | 468,000 | 1,029,000 | 1,173,000 | 1,313,000 | 6,582,000 | 1,809,000 | 2,713,000 | 1,836,000 | 1,213,000 | 2,250,000 | 3,013,000 | 85,000 | 172,000 |
Cost Of Revenue | - | - | - | - | - | 1,537,000 | 3,162,000 | 732,000 | 138,000 | 85,000 | - | - | - | 1,000,000 | 4,000 | - | 141,000 | - | - | 600,000 | - | 2,000 |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,250,000 | 2,413,000 | 85,000 | 170,000 |
Costs and Expenses | 12.5% | 63,573,000 | 56,503,500 | 41,301,000 | 35,468,000 | 37,433,000 | 28,830,500 | 26,134,000 | 28,603,000 | 28,275,000 | 35,302,000 | 43,409,000 | 46,145,000 | 38,587,000 | 29,452,000 | 19,874,000 | 26,043,000 | 22,982,000 | 21,098,000 | 25,102,000 | - | - |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22,982,000 | 21,098,000 | 24,502,000 | 27,461,000 | 23,902,000 |
S&GA Expenses | 11.0% | 52,994,000 | 47,748,000 | 32,664,000 | 27,186,000 | 26,803,000 | 19,731,000 | 18,667,000 | 18,862,000 | 19,339,000 | 15,334,000 | 19,714,000 | 20,124,000 | 17,131,000 | 11,343,000 | 7,634,000 | 7,038,000 | 7,138,000 | 6,857,000 | 6,922,000 | 5,425,000 | 5,961,000 |
R&D Expenses | 11.1% | 10,579,000 | 9,524,000 | 8,637,000 | 8,282,000 | 9,093,000 | 9,142,000 | 7,467,000 | 9,741,000 | 8,851,000 | 20,968,000 | 23,695,000 | 26,021,000 | 20,456,000 | 18,105,000 | 12,240,000 | 18,864,000 | 15,844,000 | 14,241,000 | 17,580,000 | 22,036,000 | 17,941,000 |
EBITDA Margin | 24.6% | -0.36 | -0.48 | -0.16 | -0.62 | -0.98 | -1.20 | -12.12 | -24.70 | -36.68 | -14.94 | -13.10 | -9.51 | - | - | - | - | - | - | - | - | - |
Interest Expenses | 35.4% | 2,356,000 | 1,740,000 | 1,107,000 | 1,075,000 | 1,028,000 | 991,000 | 886,000 | 777,000 | 746,000 | 984,000 | 1,216,000 | 1,202,000 | 1,100,000 | 1,314,000 | 1,202,000 | 1,226,000 | 1,357,000 | 1,398,000 | 1,443,000 | - | 1,404,000 |
Income Taxes | -63.7% | 121,000 | 333,000 | 200,000 | - | 14,000 | - | - | 6,000 | 2,000 | - | 1,000 | 2,000 | 1,000 | 2,000 | - | - | - | - | 301,000 | -2,000 | - |
Earnings Before Taxes | 7.3% | -26,397,000 | -28,469,000 | 6,829,000 | -17,121,000 | -26,759,000 | 10,695,000 | -22,893,000 | -26,932,000 | -28,069,000 | -36,234,000 | -43,586,000 | -45,187,000 | -33,154,000 | -28,874,000 | -18,108,000 | -24,956,000 | -22,373,000 | -19,790,000 | -23,238,000 | -27,864,000 | -24,126,000 |
EBT Margin | 22.2% | -0.41 | -0.53 | -0.20 | -0.68 | -1.04 | -1.29 | -12.67 | -25.95 | -38.43 | -15.66 | -13.86 | -10.09 | - | - | - | - | - | - | - | - | - |
Net Income | 7.9% | -26,518,000 | -28,802,000 | 6,629,000 | -17,121,000 | -26,773,000 | 10,695,000 | -22,893,000 | -26,938,000 | -28,071,000 | -36,234,000 | -43,587,000 | -45,189,000 | -33,155,000 | -28,876,000 | -18,108,000 | -24,956,000 | -22,373,000 | -19,790,000 | -23,539,000 | -27,862,000 | -24,126,000 |
Net Income Margin | 22.1% | -0.41 | -0.53 | -0.20 | -0.68 | -1.05 | -1.29 | -12.67 | -25.95 | -38.43 | -15.66 | -13.86 | -10.09 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -309.5% | -35,872,000 | -8,761,000 | -21,661,000 | -14,830,000 | -44,809,000 | 14,229,000 | -25,427,000 | -31,281,000 | -27,620,000 | -39,374,000 | -35,034,000 | -35,015,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 15.1% | 342 | 298 | 289 | 211 | 217 | 190 | 145 | 132 | 129 | 150 | 171 | 205 | 210 | 202 | 199 | 217 | 235 | 260 | 119 | 138 | 166 |
Current Assets | 4.8% | 258 | 246 | 241 | 162 | 167 | 154 | 120 | 114 | 114 | 134 | 153 | 186 | 205 | 195 | 194 | 212 | 229 | 252 | 111 | 127 | 154 |
Cash Equivalents | 68.4% | 36.00 | 21.00 | 34.00 | 30.00 | 92.00 | 96.00 | 62.00 | 53.00 | 47.00 | 72.00 | 75.00 | 87.00 | 84.00 | 91.00 | 91.00 | 100 | 106 | 181 | 93.00 | 90.00 | 92.00 |
Inventory | 59.4% | 79.00 | 49.00 | - | - | - | - | - | 5.00 | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | 1.0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 |
Liabilities | 46.4% | 191 | 131 | 98.00 | 88.00 | 92.00 | 92.00 | 78.00 | 79.00 | 65.00 | 67.00 | 89.00 | 87.00 | 79.00 | 75.00 | 67.00 | 71.00 | 68.00 | 73.00 | 70.00 | 69.00 | 74.00 |
Current Liabilities | 12.9% | 57.00 | 50.00 | 44.00 | 62.00 | 63.00 | 66.00 | 52.00 | 49.00 | 48.00 | 53.00 | 69.00 | 58.00 | 42.00 | 28.00 | 17.00 | 34.00 | 23.00 | 22.00 | 18.00 | 16.00 | 21.00 |
LT Debt, Current | - | - | - | - | - | - | - | 27.00 | 26.00 | 26.00 | 32.00 | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -9.5% | 151 | 167 | 191 | 123 | 125 | 98.00 | 67.00 | 53.00 | 64.00 | 83.00 | 81.00 | 118 | 131 | 126 | 131 | 146 | 168 | 187 | 49.00 | 69.00 | 92.00 |
Retained Earnings | -3.1% | -872 | -846 | -817 | -824 | -806 | -780 | -790 | -767 | -741 | -712 | -676 | -633 | -587 | -554 | -525 | -507 | -482 | -460 | -440 | -417 | -391 |
Additional Paid-In Capital | 1.1% | 1,024 | 1,013 | 1,009 | 947 | 932 | 879 | 858 | 821 | 805 | 796 | 758 | 751 | 719 | 681 | 657 | 654 | 651 | 647 | 490 | 486 | 483 |
Shares Outstanding | 0.6% | 234 | 232 | 232 | 218 | 214 | 199 | 147 | 146 | 131 | 104 | 100 | 100 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 725 | - | - | - | 89.00 | - | - | - | 769 | - | - | - | 612 | - | - | - | 126 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -309.7% | -35,722 | -8,718 | -21,467 | -14,737 | -44,795 | 14,284 | -25,427 | -31,281 | -27,620 | -39,469 | -34,589 | -34,276 | -44,217 | -17,590 | -19,877 | -19,022 | -24,946 | -11,137 | -20,614 | -27,820 | -16,913 |
Share Based Compensation | 93.8% | 7,616 | 3,930 | 3,489 | 3,199 | 2,912 | 1,926 | 1,848 | 3,254 | 3,722 | 3,471 | 2,262 | 3,219 | 3,087 | 2,434 | 2,527 | 2,674 | 2,948 | 2,212 | 3,879 | 1,923 | 1,922 |
Cashflow From Investing | 91.3% | -2,572 | -29,567 | -32,697 | -59,207 | -9,777 | 1,441 | -832 | 15,474 | 2,332 | 22,096 | 18,133 | 8,234 | 2,485 | -3,570 | 9,594 | 13,417 | -50,883 | -55,461 | 23,448 | 25,405 | 29,981 |
Cashflow From Financing | 103.8% | 52,971 | 25,988 | 57,873 | 11,515 | 50,919 | 18,787 | 34,479 | 22,138 | -63.00 | 14,513 | 4,999 | 28,717 | 34,770 | 21,183 | 798 | 204 | 591 | 155,058 | 213 | 5.00 | 200 |
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Total revenues | $ 46,023 | $ 11,369 |
Cost of goods sold: | ||
Total cost of goods sold | 7,128 | 1,537 |
Operating expenses: | ||
Research and development | 10,579 | 9,093 |
Selling, general and administrative | 52,994 | 26,803 |
Total operating expenses | 63,573 | 35,896 |
Loss from operations | (24,678) | (26,064) |
Interest expense | (2,356) | (1,028) |
Non-cash interest expense related to the sale of future royalties | (1,702) | (969) |
Other income, net | 2,339 | 1,302 |
Loss before provision for income taxes | (26,397) | (26,759) |
Provision for income taxes | 121 | 14 |
Net loss | $ (26,518) | $ (26,773) |
Net loss per share of common stock - basic (in dollars per share) | $ (0.11) | $ (0.13) |
Net loss per share of common stock - diluted (in dollars per share) | $ (0.11) | $ (0.13) |
Shares used in computing net loss per share - basic (in shares) | 233,065,960 | 207,023,127 |
Shares used in computing net loss per share - diluted (in shares) | 233,065,960 | 207,023,127 |
Comprehensive loss: | ||
Net loss | $ (26,518) | $ (26,773) |
Unrealized (losses) gains on available-for-sale securities | (244) | 34 |
Comprehensive loss | (26,762) | (26,739) |
Product sales, net | ||
Revenues: | ||
Total revenues | 43,512 | 11,355 |
Cost of goods sold: | ||
Total cost of goods sold | 1,013 | 372 |
Product supply revenue | ||
Revenues: | ||
Total revenues | 2,126 | 2 |
Licensing revenue | ||
Revenues: | ||
Total revenues | 17 | 12 |
Non-cash royalty revenue related to the sale of future royalties | ||
Revenues: | ||
Total revenues | 368 | 0 |
Other cost of revenue | ||
Cost of goods sold: | ||
Total cost of goods sold | $ 6,115 | $ 1,165 |
CONDENSED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 36,147 | $ 21,470 |
Short-term investments | 166,431 | 162,829 |
Accounts receivable | 28,162 | 22,031 |
Inventory | 9,813 | 12,448 |
Prepaid commercial manufacturing | 5,519 | 18,925 |
Prepaid expenses and other current assets | 11,867 | 8,408 |
Total current assets | 257,939 | 246,111 |
Inventory, non-current | 69,045 | 37,039 |
Prepaid commercial manufacturing, non-current | 4,235 | 4,235 |
Right-of-use assets | 4,641 | 5,589 |
Property and equipment, net | 1,019 | 1,009 |
Other assets | 5,503 | 3,596 |
Total assets | 342,382 | 297,579 |
Current liabilities: | ||
Accounts payable | 17,277 | 11,138 |
Accrued compensation and benefits | 6,727 | 12,597 |
Current portion of operating lease liability | 4,314 | 4,435 |
Deferred revenue | 6,586 | 7,182 |
Accrued expenses and other current liabilities | 21,991 | 15,041 |
Total current liabilities | 56,895 | 50,393 |
Operating lease liability, net of current portion | 778 | 1,725 |
Long-term debt, net of current portion | 99,834 | 49,822 |
Deferred revenue, non-current | 12,103 | 8,644 |
Deferred royalty obligation related to the sale of future royalties | 21,881 | 20,179 |
Total liabilities | 191,491 | 130,763 |
Commitments and contingencies (Note 14) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively. | 0 | 0 |
Common stock, $0.0001 par value; 500,000,000 shares authorized; 233,959,744 and 232,453,190 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively. | 23 | 23 |
Additional paid-in capital | 1,023,610 | 1,012,773 |
Accumulated deficit | (872,722) | (846,204) |
Accumulated other comprehensive (loss) income | (20) | 224 |
Total stockholders’ equity | 150,891 | 166,816 |
Total liabilities and stockholders’ equity | $ 342,382 | $ 297,579 |
 | Mr. Michael G. Raab |
---|---|
 | ardelyx.com |
 | Biotechnology |
 | 133 |